Drug · CHEMBL79
LIDOCAINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. LIDOCAINE. Drugs and targets, record CHEMBL79. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL79
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Alphacaine, Dentipatch, Lidocaine component of emla, Lidocaine component of fortacin, Lidocaine component of lanabiotic, Lidocaine component of oraqix, Lidocaine component of pliaglis, Lidocaine component of rocephin kit, Lidocaine component of synera, Lidoderm, Lignocaine hcl, Lmx 4, Oraqix, Vagisil, Xylocaine, Xylodase, Xylotox, Ztlido
- ChEMBL
- Other names
- ALGRX 3268, ALGRX-3268, Embolex, Iontocaine, Lidocaina, Lidocainum, NSC-40030, Octocaine, Solarcaine, Xylestesin
- ChEMBL
- Open Targets' highest stage
- Approval, for 21 of its 191 diseases, from ATC, DailyMed, EMA Human Drugs and PMDA
- Open Targets
Targets10
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| SCN10A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6336 |
| SCN11A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/11280 |
| SCN1A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6323 |
| SCN2A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6326 |
| SCN3A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6328 |
| SCN4A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6329 |
| SCN5A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6331 |
| SCN7A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6332 |
| SCN8A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6334 |
| SCN9A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6335 |
Source ChEMBL
Diseases191
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 191Source Open Targets
See all 191 diseasesTrials1,668
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 24 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 165 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02726620 | Decision Support for Intraoperative Low Blood Pressure | 22,435 | 2019-05-16 | lidocaine | Its name | ClinicalTrials.gov | |
| NCT01401647 | Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia | Phase 3 | 3,024 | 2017-01-30 | lidocaine | Its name | ClinicalTrials.gov |
| NCT03472469 | MAST Trial: Multi-modal Analgesic Strategies in Trauma | Phase 4 | 1,561 | 2021-06-10 | lidocaine | Its name | ClinicalTrials.gov |
| NCT02101359 | Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery | Phase 3 | 609 | 2014-09-25 | lidocaine | Its name | ClinicalTrials.gov |
| NCT05386030 | Saypha® VOLUME Lidocaine for Midface Augmentation | Phase 3 | 562 | 2025-01-16 | saypha VOLUME Lidocaine | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT00938964 | Lidocaine For Neuroprotection During Cardiac Surgery | 550 | 2017-08-24 | lidocaine | Its name | ClinicalTrials.gov | |
| NCT01330134 | Comparison of Two Lidocaine Administration Techniques | Phase 4 | 481 | 2018-06-28 | lidocaine | Its name | ClinicalTrials.gov |
| NCT01238536 | Lumbar Epidural Steroid Injections for Spinal Stenosis Multicenter Randomized, Controlled Trial (LESS Trial) | Phase 4 | 400 | 2017-12-13 | lidocaine | Its name | ClinicalTrials.gov |
| NCT04275336 | Pharmacological and Non-pharmacological Interventions in Management of Venipuncture Pain. | 354 | 2021-10-06 | lidocaine and prilocaine | A combination that names it | ClinicalTrials.gov | |
| NCT00587483 | Amiodarone for the Prevention of Reperfusion Ventricular Fibrillation | 342 | 2011-08-09 | lidocaine | Its name | ClinicalTrials.gov |
1 to 10 of 1,668
See all 1,668 trialsComparisons in its trials365
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Hypotension Decision Support vs Usual Care Group: deaths from any cause | 158 of 4,972 | 534 of 17,463 | 22,435 | NCT02726620 | Trial comparisons |
| Hypotension Decision Support vs Usual Care Group: serious adverse events | 541 of 4,972 | 1,811 of 17,463 | 22,435 | NCT02726620 | Trial comparisons |
| Hypotension Decision Support vs Usual Care Group: Incidence of a MAP < 50 mmHg for > 20 Minutes | 85 of 4,328 | 304 of 15,624 | 19,952 | NCT02726620 | Trial comparisons |
| Hypotension Decision Support vs Usual Care Group: Usage Frequency of Cardiovascular Drugs: Glycopyrrolate | 1,257 of 4,328 | 11,093 of 15,624 | 19,952 | NCT02726620 | Trial comparisons |
| Hypotension Decision Support vs Usual Care Group: Usage Frequency of Cardiovascular Drugs: Ephinephrine | 409 of 4,328 | 1,215 of 15,624 | 19,952 | NCT02726620 | Trial comparisons |
| Hypotension Decision Support vs Usual Care Group: Incidence of a MAP < 60 mmHg | 3,798 of 4,328 | 13,779 of 15,624 | 19,952 | NCT02726620 | Trial comparisons |
| Hypotension Decision Support vs Usual Care Group: Incidence of a MAP < 50 mmHg for > 10 Minutes | 326 of 4,328 | 1,159 of 15,624 | 19,952 | NCT02726620 | Trial comparisons |
| Hypotension Decision Support vs Usual Care Group: Usage Frequency of Cardiovascular Drugs: Phenylephrine | 3,685 of 4,328 | 12,211 of 15,624 | 19,952 | NCT02726620 | Trial comparisons |
| Hypotension Decision Support vs Usual Care Group: In-hospital Mortality | 137 of 4,328 | 487 of 15,624 | 19,952 | NCT02726620 | Trial comparisons |
| Hypotension Decision Support vs Usual Care Group: Incidence of a MAP < 55 mmHg | 3,045 of 4,328 | 10,991 of 15,624 | 19,952 | NCT02726620 | Trial comparisons |
1 to 10 of 365
See all 365 comparisons in its trialsPapers from its trials962
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials10
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Trail Making Test A | 2 | 1 | ConductCognition |
| Trail Making Test B | 2 | 1 | ConductCognition |
| Verbal Learning | 2 | 1 | ConductCognition |
| Arithmetic Fluency Task | 1 | 0 | ConductCognition |
| Clock Drawing Task | 1 | 1 | ConductCognition |
| Digit Span Test | 1 | 1 | ConductCognition |
| Picture Naming Test | 1 | 1 | ConductCognition |
| Symbol Coding | 1 | 0 | ConductCognition |
| Task Switching Test | 1 | 0 | ConductCognition |
| Verbal Fluency | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL79
GET https://conductscience.org/api/drugs/v1/CHEMBL79/diseases?page=2